|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The t(14;18)(q32;q21) translocation, involving the BCL2 gene and junctional segments (JH) of the immunoglobulin heavy chain gene (IGH), constitutes the most common chromosomal translocation in non-Hodgkin's lymphoma of B-cell type.
|
9443038 |
1998 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study was planned with the aim to investigate the association between bcl-2 gene rearrangements and apoptotic changes during chemotherapy in patients with non-Hodgkin's lymphoma.
|
10074891 |
1999 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.
|
10784621 |
2000 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide.
|
10873104 |
2000 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Incidence of BCL-2 gene rearrangements in Argentinean non-Hodgkin lymphoma patients: increased frequency of breakpoints outside of MBR and MCR.
|
14757440 |
2004 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma.
|
15651174 |
2004 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ongoing clinical trials are exploring the role of Bcl-2 downregulation with oblimersen (Bcl-2 antisense) in patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia and multiple myeloma.
|
15784299 |
2005 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, two other genes, BCL6 and BCL2, which are classically related to apoptosis and non-Hodgkin lymphoma, were shown for the first time to be involved in amplification.
|
15611930 |
2005 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bcl-2 has been implicated in conferring resistance to chemotherapy in non-Hodgkin's lymphoma and is therefore a candidate prognostic marker in DLBCL.
|
16796775 |
2006 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Some evidence suggests that IL-10 might be associated with the progression of T-cell NHLs and that IL-10 may be involved in a rescue effect, protecting T cells from apoptotic cell death associated with upregulated bcl-2 expression.
|
17408400 |
2007 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Multiplex PCR for the detection of BCL-1/IGH and BCL-2/IGH gene rearrangements--clinical validation in a prospective study of blood and bone marrow in 258 patients with or suspected of non-Hodgkin's lymphoma.
|
17438702 |
2007 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
This indicates that primers for bcl-2 gene must include icr primer, whenever the bcl-2 gene is being evaluated for B-cell NHL in this part of the world and this might reduce the variability of frequency of bcl-2 gene rearrangement within and between different regions.
|
19537891 |
2009 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
High levels of BACH2 associated with lower levels of BCL2 transcript abundance in t(14;18)(q21;q34) translocation positive non-Hodgkin's lymphoma.
|
18929412 |
2009 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.
|
20352431 |
2010 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Role of polymorphisms in BCL-2 and BAX genes in modulating the risk of developing non-Hodgkin lymphoma.
|
24024471 |
2014 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
MYC/BCL2 double hit lymphoma (DHL) is a rare, recently recognised and highly aggressive subtype of non-Hodgkin lymphoma, with an affinity to involve the central nervous system and the head and neck either at initial presentation or during relapse.
|
23932423 |
2014 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thirty-two patients diagnosed with non-Hodgkin lymphoma with concurrent MYC and BCL2 translocations from 2003 to 2013 were identified.
|
25656914 |
2015 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
CTD_human |
Copper-64-labeled anti-bcl-2 PNA-peptide conjugates selectively localize to bcl-2-positive tumors in mouse models of B-cell lymphoma.
|
26239085 |
2015 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
DNA was extracted from archival CPs of B-cell NHL cases with previous fluorescence in situ hybridization (FISH) assays for MYC rearrangement and/or IGH/BCL-2 translocation.
|
25807917 |
2015 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mechanism of action of EBV, Bcl-2, p53, c-Myc and Rb in non-Hodgkin's lymphoma.
|
27049262 |
2016 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
A recent phase I first-in-human study of the BCL-2 inhibitor venetoclax in non-Hodgkin lymphoma showed an overall response rate of 44%.
|
29666304 |
2018 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma (NHL) with genetic alterations of BCL-2, KMT2B, and KMT6.
|
30693983 |
2019 |